Novel therapeutic approaches for multiple myeloma

Immunological Reviews

Volumn 194, Issue , 2003, Pages 164-176

  Hideshima, Teru ^a   Richardson, Paul ^a   Anderson, Kenneth C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACYLGLYCEROPHOSPHOCHOLINE ACYLTRANSFERASE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 METHOXYESTRADIOL; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; AE 941; ALPHA N (PHTHALIMIDO)GLUTARIMIDE; ARSENIC TRIOXIDE; BORTEZOMIB; EPOTHILONE B; GELDANAMYCIN; GLUTAMIC ACID DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; INTERLEUKIN 15; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE BETA INHIBITOR; OBLIMERSEN; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 1BETA; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1ALPHA; TELOMERASE INHIBITOR; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB;

ABDOMINAL PAIN; ANEMIA; ANIMAL DISEASE; BONE MARROW; CELL GROWTH; CELL MIGRATION; CELL SURVIVAL; DIARRHEA; DRUG POTENCY; DRUG RESISTANCE; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GROWTH REGULATION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; LEUKOPENIA; MULTIPLE MYELOMA; NEUROPATHY; PHOCOMELIA; PRIORITY JOURNAL; REVIEW; TARGET CELL; TERATOGENICITY; THROMBOCYTOPENIA; UNITED STATES;

ANIMALS; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION;

EID: 0037660963     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2003.00053.x     Document Type: Review

References (148)

1. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-342.
2. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998;16:3832-3842.
3. Fermand JP, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-3136.
4. Lenhoff S, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000;95:7-11.
5. Attal M, Harousseau JL. Randomized trial experience of the Intergroupe Francophone du Myelome. Semin Hematol 2001;38:226-230.
6. Desikan R, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000;95:4008-4010.
7. Fermand JP, et al. In single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABST) transplantation using unselected of CD34 enriched ABSC: preliminary results or a two by two designed randomized trial in 230 young patients with multiple myeloma (MM). Blood 2001;98:815a.
8. Attal M, et al. Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the 'Intergroupe Francophone du Myelome' (IMF94). Blood 2002;100:5a.
9. Massaia M, et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999;94:673-683.
10. Gahrton G, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991;325:1267-1273.
11. Gahrton G, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001;113:209-216.
12. Alyea E, et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001;98:934-939.
13. Badros A, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2574-2579.
14. Kroger N, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002;100:755-760.
15. Rajkumar SV, Kyle RA, Gertz MA. Myeloma and the newly diagnosed patient: a focus on treatment and management. Semin Oncol 2002;29:5-10.
16. Berenson JR, et al. American Society of Clinical Oncology Clinical Practice Guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-3736.
17. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175-187.
18. Anderson KC. Targeted therapy for multiple myeloma. Semin Hematol 2001;38:286-297.
19. Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 1997;11:27-42.
20. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-1667.
21. kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000;19:4319-4327.
22. Uchiyama H, Barut BA, Chauhan D, Cannistra SA, Anderson KC. Characterization of adhesion molecules on human myeloma cell lines. Blood 1992;80:2306-2314.
23. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82:3712-3720.
24. Chauhan D, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood 1996;87:1104-1112.
25. Hideshima T, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-16647.
26. Urashima M, et al. Transforming growth factor-β1: differential effects on multiple myeloma versus normal B cells. Blood 1996;87:1928-1938.
27. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor-α in the pathogenesis of human multiple myeloma: therapeutic applications. Oncogene 2001;20:4519-4527.
28. Gupta D, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15:1950-1961.
29. Ogata A, et al. Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997;159:2212-2221.
30. Chauhan D, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997;89:227-234.
31. Chauhan D, et al. Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells. J Biol Chem 1997;272:29995-29997.
32. Chauhan D, et al. RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene 1999;18:6733-6740.
33. Podar K, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428-435.
34. Mitsiades CS, et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002;21:5673-5683.
35. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequdae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001;20:5991-6000.
36. Podar K, et al. Vascular endothelial growth factor-indnced migration of multiple myeloma cells is associated with β1 integrin- and phosphatidylinositol 3-kmase-dependent PKCα activation. J Biol Chem 2002;277:7875-7881.
37. Hideshima T, et al. The biologic sequelae of stromal cell-derived factor-1a in multiple myeloma. Mol Cancer Ther 2002;1:539-544.
38. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 1995;85:1903-1912.
39. Costes V, Pottier M, Lu ZY, Rossi JF, Bataille R, Klein B. Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol 1998;103:1152-1160.
40. Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 1999;13:1117-1125.
41. Dankbar B, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000;95:2630-2636.
42. Hideshima T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2003;101:703-705.
43. Catlett-Falcone R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-115.
44. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999;29:3945-3950.
45. Wei LH, et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI3-K/Akt pathway. Oncogene 2001;20:5799-5809.
46. Epling-Burnette PK, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001;107:351-362.
47. Oshiro MM, et al. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin Cancer Res 2001;7:4262-4271.
48. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res 2000;60:6763-6770.
49. Chauhan D, Hideshima T, Rosen S, Reed JC, Kharbanda S, Anderson KC. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J Biol Chem 2001;276:24453-24456.
50. Chauhan D, et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000;275:27845-27850.
51. Chauhan D, et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 2002;21:1346-1358.
52. Chauhan D, Anderson KC. Apoptosis in multiple myeloma: therapeutic implications. Apoptosis 2001;6:47-55.
53. Chauhan D, et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma (MM) cells using ohgonucleotide array. Blood (in press).
54. Reimold AM, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001;412:300-307.
55. Claudio JO, et al. A molecular compendium of genes expressed in multiple myeloma. Blood 2002;100:2175-2186.
56. Urashima M, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997;90:754-765.
57. Pulkki K, Pelliniemi TT, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group. Br J Haematol 1996;92:370-374.
58. Kyrtsonis MC, et al. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br J Haematol 1996;93:398-400.
59. Stasi R, Brunetti M, Parma A, Di Giulio C, Terzoli E, Pagano A. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer 1998;82:1860-1866.
60. Pelliniemi TT, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995;85:765-771.
61. Calasanz MJ, et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer 1997;18:84-93.
62. Tricot G, et al. Predicting long-term (> or =5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002;116:211-217.
63. Ogata A, Anderson KC. Therapeutic strategies for inhibition of interleukin-6 mediated multiple myeloma cell growth. Leuk Res 1996;20:303-307.
64. Corral LG, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999;163:380-386.
65. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927-937.
66. Tai YT, et al. CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood 2002;99:1419-1427.
67. Lin B, et al. The vascular endothelial growth factor receptor kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2002;62:5019-5026.
68. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000;96:2856-2861.
69. Qiang YW, Kopantzev E, Rudikoff S. Insulin-like growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 2002;99:4138-4146.
70. Akiyama M, et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 2002;62:3876-3882.
71. Mitsiades CS, et al. The IGF/IGF-1R system is a major therapeutic target for multiple myeloma, other hematologic malignancies and solid tumors. Blood 2002;100:170a.
72. Lu ZY, et al. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 1995;85:2521-2527.
73. Gu ZJ, et al. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 1996;88:3972-3986.
74. Choi SJ, et al. Macrophage inflammatory protein 1-α is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-675.
75. Abe M, et al. Role for macrophage inflammatory protein (MIP)-1α and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 2002;100:2195-2202.
76. Hjorth-Hansen H, Waage A, Borset M. Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells. Br J Haematol 1999;106:28-34.
77. Tinhofer I, Marschitz I, Henn T, Egle A, Greil R. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 2000;95:610-618.
78. Brenne AT, Baade Ro T, Waage A, Sundan A, Borset M, Hjorth-Hansen H. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 2002;99:3756-3762.
79. Chauhan D, et al. Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells. J Exp Med 1995;182:1801-1806.
80. Nishimoto N, et al. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J Exp Med 1994;179:1343-1347.
81. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996;35:969-979.
82. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J Exp Med 1991;173:699-703.
83. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor-α by enhancing mRNA degradation. J Exp Med 1993;177:1675-1680.
84. Sampaio EP, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408-414.
85. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Nad Acad Sci USA 1994;91:4082-4085.
86. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-978.
87. Kotoh T, et al. Anti-angiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery 1999;125:536-544.
88. Hideshima T, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-2950.
89. Mitsiades N, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99: 4525-4530.
90. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J Biol Chem 2001;276:22382-22387.
91. Chauhan D, et al. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene 1997;15:837-843.
92. Haslett PA, et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses 1999;15:1169-1179.
93. Davies FE, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-216.
94. Lentzsch S, et al. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res 2002;62:2300-2305.
95. Treston AM, Swartz GM, Conner B, Shah J, Pribluda VS. Pre-clinical evaluation of a thalidomide analog with activity against multiple myeloma and solid tumors - ENMD-0995 (S- (-)-3-(3-ammo-phthalimido)-glutarimide). Blood 2002;100:816a.
96. Singhal S, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
97. Alexanian R, Weber D. Thalidomide for resistant and relapsing myeloma. Semin Hematol 2000;37:22-25.
98. Rajkumar SV, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000;75:897-901.
99. Rajkumar SV, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-4323.
100. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16-19.
101. Richardson P, et al. Immunomodulatory derivative of thalidomide CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-3067.
102. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 1996;274:1652-1959.
103. Kisselv AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;21:1-20.
104. Hideshima T, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma. Cancer Res 2001;61:3071-3076.
105. Mitsiades N, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002;99:14374-14379.
106. Hideshima T, et al. Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-1534.
107. LeBlanc R, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
108. Mitsiades N, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377-2380.
109. Hideshima T, et al. Caspase-dependent cleavage of gp130/interleukin-6 receptor b-subunit in multiple myeloma: therapeutic implications (submitted for publication).
110. Richardson P, et al. A phase II multicenter study of the proteasome inhibitor Bortezomib (Velcade™, formerly PS-341) in multiple myeloma patients (pts) with relapsed/refractory disease. Blood 2002;100:104a.
111. Hayashi T, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002;1:851-860.
112. 3) on myeloma cells. Leuk Res 2001;25:227-325.
113. Hussein MA. Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma. Med Oncol 2001;18:239-242.
114. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001;98:805-813.
115. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 1994;91:3964-3968.
116. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81-86.
117. Chauhan D, et al. 2-Methoxyestradiol (2ME2) acts direcdy on tumor cells and in the bone marrow microenvironment to overcome drug resistance in multiple myeloma. Blood 2002;100:2187-2194.
118. Hideshima T, et al. Induction of apoptosis by lysophosphatidic acid acyltransferase (LPAAT)-β inhibitors in multiple myeloma (MM). Blood 2002;100:813a.
119. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728-733.
120. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 1992;89:6403-6407.
121. Karp JE, Kaufmann SH, Adjei AA, Lancet JE, Wright JJ, End DW. Current status of clinical trials of farnesyltransferase inhibitors. Curr Opin Oncol 2001;13:470-476.
122. Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 2001;7:1438-1445.
123. Karp JE, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97:3361-3369.
124. Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) cell lines and patient tumor cells. Blood 2001;98:376a.
125. Cadey L, et al. LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma: results of a preclinical evaluation in vitro and in vivo. Blood 2002;100:106a.
126. Mitsiades CS, Mitsiades N, Poulaki V, Akiyama M, Treon SP, Anderson KC. The HSP90 molecular chaperone as a novel therapeutic target in hematologic malignancies. Blood 2001;98:377a.
127. Sangfelt O, et al. Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. Int J Cancer 1995;63:190-192.
128. Gazitt Y, Rothenberg ML, Hilsenbeck SG, Fey V, Thomas C, Montegorarey W. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol 1998;11:839-848.
129. Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucl Acid Drug Dev 2002;12:193-213.
130. De Cesaris P, Starace D, Riccioli A, Padula F, Filippin A. Tumor necrosis factor-α induces interleukin-6 production and integrin ligand expression by distinct transcription pathways. J Biol Chem 1998;273:7566-7571.
131. Craig R, et al. p38 MAPK and NF-κB collaborate to induce interleukin-6 gene expression and release. J Biol Chem 2000;275:23814-23824.
132. Chae HJ, et al. The p38 mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumor necrosis factor in osteoblasts. Bone 2001;28:45-53.
133. Mitsiades CS, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001;98:795-804.
134. Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 2002;99:2162-2171.
135. Ogawa M, et al. Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res 2000;60:4262-4269.
136. van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002;16:1362-1371.
137. Mitsiades CS, et al. HMG-CoA inhibitors (statins) induce growth arrest, apoptosis of multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) cells and enhance their sensitivity to conventional or novel therapies. Molecular prolong of HMG-CoA inhibition in MM/WM and framework for translation to therapeutic application. Blood 2002;100:597a.
138. Treon SP, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002;25:72-81.
139. Raje N, et al. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood 1999;93:1487-1495.
140. Brown RD, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001;98:2992-2998.
141. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA 2002;99:13009-13013.
142. Bendandi M, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5:1171-1177.
143. Lira SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 1999;83:215-222.
144. Reichardt VL, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999;93:2411-2419.
145. Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000;6:621-627.
146. Thurner B, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-1678.
147. Grosman DD, et al. Dendritic cell (DC)-tumor fusions generated with mature as compared to immature DC potently induce myeloma specific immunity. Blood 2002;100:399a.
148. Hayashi T, et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 2002;100:400a.